Analysts Issue Forecasts for Nuvation Bio Q1 Earnings

Posted by Brenda Bartman on Aug 11th, 2026

Nuvation Bio Inc. (NYSE:NUVB – Free Report) – HC Wainwright issued their Q1 2027 EPS estimates for shares of Nuvation Bio in a note issued to investors on Friday, August 7th. HC Wainwright analyst R. Burns forecasts that the company will post earnings per share of $0.01 for the quarter. HC Wainwright has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.11) EPS.

Nuvation Bio (NYSE:NUVB – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%.The business had revenue of $31.69 million for the quarter, compared to the consensus estimate of $27.03 million.

Other analysts have also recently issued research reports about the stock. Citigroup reissued a “market outperform” rating on shares of Nuvation Bio in a research note on Wednesday, June 10th. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvation Bio in a report on Friday, July 17th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research report on Thursday, July 23rd. Finally, B. Riley Financial reissued a “buy” rating on shares of Nuvation Bio in a research note on Friday. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvation Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

Read Our Latest Analysis on Nuvation Bio

Nuvation Bio Price Performance

NUVB stock opened at $6.57 on Monday. The company has a market capitalization of $2.29 billion, a P/E ratio of -14.93 and a beta of 1.52. The company has a fifty day moving average price of $5.79 and a 200-day moving average price of $5.24. The company has a debt-to-equity ratio of 0.96, a quick ratio of 8.14 and a current ratio of 8.37. Nuvation Bio has a 52-week low of $2.18 and a 52-week high of $9.75.

Insiders Place Their Bets

In related news, CFO Philippe Sauvage sold 47,668 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the completion of the sale, the chief financial officer owned 12,673 shares of the company’s stock, valued at $76,164.73. This trade represents a 79.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Mashal bought 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The shares were acquired at an average cost of $4.73 per share, with a total value of $118,250.00. Following the purchase, the director directly owned 225,000 shares of the company’s stock, valued at $1,064,250. This trade represents a 12.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders sold 235,668 shares of company stock valued at $1,419,495. Insiders own 30.11% of the company’s stock.

Institutional Trading of Nuvation Bio

Large investors have recently modified their holdings of the stock. HighTower Advisors LLC raised its stake in Nuvation Bio by 9.8% during the 4th quarter. HighTower Advisors LLC now owns 22,457 shares of the company’s stock worth $201,000 after buying an additional 2,007 shares during the period. Tema ETFs LLC increased its holdings in shares of Nuvation Bio by 0.7% during the second quarter. Tema ETFs LLC now owns 395,313 shares of the company’s stock valued at $2,245,000 after acquiring an additional 2,559 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Nuvation Bio by 51.9% during the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock worth $28,000 after purchasing an additional 2,597 shares during the period. Russell Investments Group Ltd. raised its position in shares of Nuvation Bio by 17.7% during the fourth quarter. Russell Investments Group Ltd. now owns 24,456 shares of the company’s stock worth $219,000 after purchasing an additional 3,681 shares during the period. Finally, Meridian Wealth Management LLC lifted its holdings in shares of Nuvation Bio by 3.8% in the 4th quarter. Meridian Wealth Management LLC now owns 113,565 shares of the company’s stock worth $1,018,000 after purchasing an additional 4,200 shares in the last quarter. Institutional investors and hedge funds own 61.67% of the company’s stock.

Nuvation Bio Company Profile

(Get Free Report)

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.